



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

| | |
|---------------|----------------------------|
| Last Trade: | 38.02 |
| Trade Time: | 3:59 PM ET Jan 19, 2018 |
| Change: | 1.90 (+5.260%) |
| Day Range | 35.44 - 38.03 |
| 52-Week Range | 24.66 - 49.16 |
| Volume | 1,599,499 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius c... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 5, 2018*
[Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)
- Jan 2, 2018*
[Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications](#)
- Dec 15, 2017*
[Radius Health Announces that the Committee for Medicinal Products for Human Use \(CHMP\) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture](#)
- Dec 11, 2017*
[Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry](#)
- Dec 7, 2017*
[Radius Investigational Drug Elacestrant \(RAD1901\) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 24, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 2, 2017*
[Quarterly Report \(10-Q\)](#)